When just the prospective evidence was considered, all pooled effect estimates were consistent with the null hypothesis accept for a weak inverse association between leptin and overall prostate cancer (3% decreased risk per 2.5 ng/ml increase in leptin). This evidence concerns the gene LEP and prostate cancer.